|
(Pfizer subfamily B)
|
1.1
|
2 (B, two ST-32 cc)
|
| |
1.4
|
5 (B, four ST-41/44 cc, one ST-35 cc)
|
| |
1.12
|
2 (B, one UAa; C, one ST-11 cc)
|
| |
1.13
|
5 (B, one ST-60 cc, one ST-254 cc, two ST-1157 cc, one UA)
|
| |
1.14
|
1 (B, ST-41/44 cc)
|
| |
1.15
|
152 (B, 152 ST-269 cc)
|
| |
1.100
|
1 (B, ST-41/44 cc)
|
| |
1.110
|
1 (B, UA)
|
| |
1.129
|
1 (C, ST-11 cc)
|
| |
1.144
|
1 (B, ST-32 cc)
|
| |
1.218
|
1 (C, ST-11 cc)
|
| |
1.249
|
1 (B, ST-269 cc)
|
| |
1.278
|
1 (Y, ST-167 cc)
|
| |
1.410
|
4 (B, four ST-41/44 cc)
|
| |
1.687
|
1 (B, ST-41/44 cc)
|
|
Novartis variant 2
|
2.16
|
15 (3B, three ST-35 cc; 1C, ST-11 cc; 2Y, one ST-22 cc; one UA; 9W, nine ST-22 cc)
|
|
(Pfizer subfamily A)
| | |
| |
2.19
|
32 (31B, five ST-269 cc; 26 ST-41/44 cc; 1×, one ST-32 cc)
|
| |
2.21
|
1 (Y, ST-174 cc)
|
| |
2.22
|
1 (B, ST-32 cc)
|
| |
2.23
|
6 (3B, two ST-41/44 CC; one ST-37 cc; 3Y, one ST-167 cc; two UA)
|
| |
2.24
|
5 (4B, two ST-41/44 cc, two UA; 1Y, ST-167 cc)
|
| |
2.25
|
9 (1B, ST-103 cc; 7Y, six ST-23 cc; one ST-167 cc; 1 W, ST-22 cc)
|
| |
2.102
|
2 (1B, ST-213 cc; 1C, ST-11 cc)
|
| |
2.106
|
1 (B, UA)
|
| |
2.527
|
1 (B, UA)
|
| |
2.629
|
1 (Y, UA)
|
| |
2.632
|
1 (B, ST-41/44 cc)
|
|
Novartis variant 3
|
3.30
|
2 (B, ST-41/44 cc, ST-32 cc)
|
|
(Pfizer subfamily A)
|
3.47
|
2 (B, two ST-461 cc)
|
| |
3.555
|
1 (B, UA)
|
|
No peptide
|
allele 669
|
2 (C, two ST-11 cc)
|
| |
allele 755
|
1 (B, ST-269 cc)
|
|
Recombination
|
disrupted gene
|
1 (B, UA)
|
